Skip to main content
SpringerLink
Log in
Book cover

The Human Gut-Liver-Axis in Health and Disease pp 89–104Cite as

The Role of the Bacterial Microbiota in Alcoholic and Non-alcoholic Fatty Liver Disease

  • 1060 Accesses

Abstract

The liver and the gut closely interact as there is a bi-directional exchange of both microbial and host compounds between the two organs. In this chapter we will describe features of the gut-liver-axis and the impact of the bacterial microbiota on different stages of alcoholic and non-alcoholic (ALD, NAFLD) fatty liver diseases.

Keywords

  • Gut microbiota
  • NAFLD
  • NASH
  • ALD
  • Cirrhosis
  • Hepatocellular carcinoma
  • Bile acids
  • Leaky gut barrier

This is a preview of subscription content, access via your institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Sender R, Fuchs S, Milo R. Revised estimates for the number of human and Bacteria cells in the body. PLoS Biol. 2016;14(8):1–14.

    CrossRef  CAS  Google Scholar 

  2. Li J, Jia H, Cai X, Zhong H, Feng Q, Sunagawa S, et al. An integrated catalog of reference genes in the human gut microbiome. Nat Biotechnol. 2014;32(8):834–41.

    CrossRef  CAS  PubMed  Google Scholar 

  3. Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med. 2016;375(24):2369–79.

    CrossRef  CAS  PubMed  Google Scholar 

  4. Wahlström A, Sayin SI, Marschall HU, Bäckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016;24(1):41–50.

    CrossRef  PubMed  CAS  Google Scholar 

  5. Llorente C, Schnabl B. The gut microbiota and liver disease. Cell Mol Gastroenterol Hepatol. 2015;1(3):275–84.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  6. Davenport ER, Sanders JG, Song SJ, Amato KR, Clark AG, Knight R. The human microbiome in evolution. BMC Biol. 2017;15(1):127.

    Google Scholar 

  7. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027–131.

    CrossRef  PubMed  Google Scholar 

  8. Hollister EB, Gao C, Versalovic J. Compositional and functional features of the gastrointerstinal microbiome and their effects on human health. Gastroenterology. 2015;146(6):1449–58.

    CrossRef  Google Scholar 

  9. Aron-Wisnewsky J, Prifti E, Belda E, Ichou F, Kayser BD, Dao MC, et al. Major microbiota dysbiosis in severe obesity: fate after bariatric surgery. Gut. Published Online First: 13 June 2018. https://doi.org/10.1136/gutjnl-2018-316103.

  10. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500(7464):541–6.

    CrossRef  CAS  PubMed  Google Scholar 

  11. Clemente JC, Ursell LK, Parfrey LW, Knight R. The impact of the gut microbiota on human health: an integrative view. Cell. 2012;148(6):1258–70.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  12. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014;146(6):1513–24.

    CrossRef  CAS  PubMed  Google Scholar 

  13. Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, et al. The gut–liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15(7):397–411.

    CrossRef  CAS  Google Scholar 

  14. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956–65.

    CrossRef  CAS  PubMed  Google Scholar 

  15. Courson A, Jones GM, Twilla JD. Treatment of acute hepatic encephalopathy: comparing the effects of adding rifaximin to lactulose on patient outcomes. J Pharm Pract. 2014;29(3):212–7.

    CrossRef  Google Scholar 

  16. Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, Ladas SD. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol. 2013;28(3):450–5.

    CrossRef  CAS  PubMed  Google Scholar 

  17. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071–81.

    CrossRef  CAS  PubMed  Google Scholar 

  18. Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M. Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Hepatology. 2017;65(1):350–62.

    CrossRef  PubMed  Google Scholar 

  19. Maurice CF, Haiser HJ, Turnbaugh PJ. Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell. 2013;152(1–2):39–50.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  20. Zarrinpar A, Loomba R. Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2012;36(10):909–21.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  21. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009;10(3):167–77.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  22. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 2000;102(6):731–44.

    CrossRef  CAS  PubMed  Google Scholar 

  23. Pols TWH, Noriega LG, Nomura M, Auwerx J, Schoonjans K. The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J Hepatol. 2011;54(6):1263–72.

    CrossRef  CAS  PubMed  Google Scholar 

  24. Inagaki T, Moschetta A, Lee Y-K, Peng L, Zhao G, Downes M, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A. 2006;103(10):3920–5.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  25. Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13(7):412–25.

    CrossRef  CAS  Google Scholar 

  26. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444(7122):1022–3.

    CrossRef  CAS  PubMed  Google Scholar 

  27. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482(7384):179–85.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  28. Jiang W, Wu N, Wang X, Chi Y, Zhang Y, Qiu X, et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep. 2015;5:8096.

    Google Scholar 

  29. Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014;513(7516):59–64.

    CrossRef  CAS  PubMed  Google Scholar 

  30. Rothschild D, Weissbrod O, Barkan E, Kurilshikov A, Korem T, Zeevi D, et al. Environment dominates over host genetics in shaping human gut microbiota. Nature. 2018;555(7695):210–5.

    Google Scholar 

  31. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457(7228):480–4.

    CrossRef  PubMed  PubMed Central  CAS  Google Scholar 

  32. Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A. 2007;104(3):979–84.

    CrossRef  CAS  Google Scholar 

  33. Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101(44):15718–23.

    CrossRef  CAS  Google Scholar 

  34. Brandl K, Plitas G, Mihu CN, Ubeda C, Jia T, Fleisher M, et al. Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature. 2008;455(7214):804–7.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  35. Cho I, Yamanishi S, Cox L, Methé BA, Zavadil J, Li K, et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature. 2012;488(7413):621–6.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  36. Card T, Logan RFA, Rodrigues LC, Wheeler JG. Antibiotic use and the development of Crohn’s disease. Gut. 2004;53(2):246–50.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  37. Gilat T, Hacohen D, Lilos P, Langman MJ. Childhood factors in ulcerative colitis and Crohn’s disease. An international cooperative study. Scand J Gastroenterol. 1987;22(8):1009–24.

    CrossRef  CAS  PubMed  Google Scholar 

  38. Kurilshikov A, Wijmenga C, Fu J, Zhernakova A. Host genetics and gut microbiome: challenges and perspectives. Trends Immunol. 2017;38(9):633–47.

    CrossRef  CAS  PubMed  Google Scholar 

  39. Yan AW, Fouts DE, Brandl J, Stärkel P, Torralba M, Schott E, et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology. 2011;53(1):96–105.

    CrossRef  PubMed  Google Scholar 

  40. Bull-Otterson L, Feng W, Kirpich I, Wang Y, Qin X, Liu Y, et al. Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment. PLoS One. 2013;8(1):e53028.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  41. Raman M, Ahmed I, Gillevet PM, Probert CS, Ratcliffe NM, Smith S, et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2013;11(7):868–75.

    CrossRef  CAS  Google Scholar 

  42. Mutlu EA, Gillevet PM, Rangwala H, Sikaroodi M, Naqvi A, Engen PA, et al. Colonic microbiome is altered in alcoholism. Am J Physiol Gastrointest Liver Physiol. 2012;302(9):G966–78.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  43. Wang Y, Kirpich I, Liu Y, Ma Z, Barve S, McClain CJ, et al. Lactobacillus rhamnosus GG treatment potentiates intestinal hypoxia-inducible factor, promotes intestinal integrity and ameliorates alcohol-induced liver injury. Am J Pathol. 2011;179(6):2866–75.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  44. Chen P, Torralba M, Tan J, Embree M, Zengler K, Stärkel P, et al. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology. 2015;148(1):203–14.

    CrossRef  PubMed  CAS  Google Scholar 

  45. Brenner DA, Paik Y-HH, Schnabl B. Role of gut microbiota in liver disease. J Clin Gastroenterol. 2015;49 Suppl 1(December):25–7.

    CrossRef  CAS  Google Scholar 

  46. Jumpertz R, Le DS, Turnbaugh PJ, Trinidad C, Bogardus C, Gordon JI, et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr. 2011;94(1):58–65.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  47. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49(6):1877–87.

    CrossRef  CAS  PubMed  Google Scholar 

  48. Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63(3):764–75.

    CrossRef  CAS  PubMed  Google Scholar 

  49. Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab. 2017;25(5):1054–62.

    Google Scholar 

  50. De Minicis S, Rychlicki C, Agostinelli L, Saccomanno S, Candelaresi C, Trozzi L, et al. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology. 2014;59(5):1738–49.

    CrossRef  CAS  PubMed  Google Scholar 

  51. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57(2):601–9.

    CrossRef  CAS  PubMed  Google Scholar 

  52. Giannelli V, Di Gregorio V, Iebba V, Giusto M, Schippa S, Merli M, et al. Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis. World J Gastroenterol. 2014;20(45):16795–810.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  53. Bauer TM, Schwacha H, Steinbruckner B, Brinkmann FE, Ditzen AK, Aponte JJ, et al. Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia. Am J Gastroenterol. 2002;97(9):2364–70.

    CrossRef  PubMed  Google Scholar 

  54. Bajaj JS, Betrapally NS, Hylemon PB, Heuman DM, Daita K, White MB, et al. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. Hepatology. 2015;62(4):1260–71.

    CrossRef  CAS  PubMed  Google Scholar 

  55. Maekawa T, Krauss J, Abe T, Jotwani R, Triantafilou M, Triantafilou K, et al. Porphyromonas gingivalis manipulates complement and TLR signaling to uncouple bacterial clearance from inflammation and promote dysbiosis. Cell Host Microbe. 2014;15(6):768–78.

    CrossRef  CAS  Google Scholar 

  56. Naka S, Hatakeyama R, Takashima Y, Matsumoto-Nakano M, Nomura R, Nakano K. Contributions of Streptococcus mutans Cnm and PA antigens to aggravation of non-alcoholic steatohepatitis in mice. Sci Rep. 2016;6(1):36886.

    Google Scholar 

  57. Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13(11):800–12.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  58. Huang Y, Fan X-G, Wang Z-M, Zhou J-H, Tian X-F, Li N. Identification of helicobacter species in human liver samples from patients with primary hepatocellular carcinoma. J Clin Pathol. 2004;57(12):1273–7.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  59. Ward JM, Fox JG, Anver MR, Haines DC, George CV, Collins MJ, et al. Chronic active hepatitis and associated liver tumors in mice caused by a presistent bacterial infection with a novel Helicobacter species. J Natl Cancer Inst. 1994;86(16):1222–7.

    CrossRef  CAS  PubMed  Google Scholar 

  60. Odenwald MA, Turner JR. The intestinal epithelial barrier: a therapeutic target? Nat Rev Gastroenterol Hepatol. 2016;14(1):9–21.

    CrossRef  PubMed  PubMed Central  CAS  Google Scholar 

  61. Palm NW, De Zoete MR, Cullen TW, Barry NA, Stefanowski J, Hao L, et al. Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease. Cell. 2014;158(5):1000–10.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  62. Gallo RL, Hooper LV. Epithelial antimicrobial defence of the skin and intestine. Nat Rev Immunol. 2012;12(7):503–16.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  63. Wang L, Fouts DE, Stärkel P, Hartmann P, Chen P, Llorente C, et al. Intestinal REG3 lectins protect against alcoholic steatohepatitis by reducing mucosa-associated microbiota and preventing bacterial translocation. Cell Host Microbe. 2016;19(2):227–39.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  64. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482(7384):179–85.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  65. Abreu MT. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol. 2010;10(2):131–43.

    CrossRef  CAS  PubMed  Google Scholar 

  66. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll- like receptors is required for intestinal homeostasis. Cell. 2015;118(February):229–41.

    Google Scholar 

  67. Graham CE, Cruz MR, Garsin DA, Lorenz MC. Enterococcus faecalis bacteriocin EntV inhibits hyphal morphogenesis, biofilm formation, and virulence of Candida albicans. Proc Natl Acad Sci U S A. 2017;114(17):4507–12.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  68. Cresci GA, Glueck B, McMullen MR, Xin W, Allende D, Nagy LE. Prophylactic tributyrin treatment mitigates chronic-binge ethanol-induced intestinal barrier and liver injury. J Gastroenterol Hepatol. 2017;32(9):1587–97.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  69. Cresci GA, Bush K, Nagy LE. Tributyrin supplementation protects mice from acute ethanol-induced gut injury. Alcohol Clin Exp Res. 2014;38(6):1489–501.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  70. Chen RC, Xu LM, Du SJ, Huang SS, Wu H, Dong JJ, et al. Lactobacillus rhamnosus GG supernatant promotes intestinal barrier function, balances Tregand TH17 cells and ameliorates hepatic injury in a mouse model of chronic-binge alcohol feeding. Toxicol Lett. 2016;241:103–10.

    CrossRef  CAS  PubMed  Google Scholar 

  71. Forsyth CB, Farhadi A, Jakate SM, Tang Y, Shaikh M, Keshavarzian A. Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis. Alcohol. 2009;43(2):163–72.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  72. Keshavarzian A, Holmes EW, Patel M, Iber F, Fields JZ, Pethkar S. Leaky gut in alcoholic cirrhosis: a possible mechanism for alcohol-induced liver damage. Am J Gastroenterol. 1999;94(1):200–7.

    CrossRef  CAS  PubMed  Google Scholar 

  73. Leclercq S, Cani PD, Neyrinck AM, Stärkel P, Jamar F, Mikolajczak M, et al. Role of intestinal permeability and inflammation in the biological and behavioral control of alcohol-dependent subjects. Brain Behav Immun. 2012;26(6):911–8.

    CrossRef  CAS  PubMed  Google Scholar 

  74. Ying W, Jing T, Bing C, Baifang W, Dai Z, Bingyuan W. Effects of alcohol on intestinal epithelial barrier permeability and expression of tight junction-associated proteins. Mol Med Rep. 2014;9(6):2352–6.

    CrossRef  CAS  Google Scholar 

  75. Elamin EE, Masclee AA, Dekker J, Jonkers DM. Ethanol metabolism and its effects on the intestinal epithelial barrier. Nutr Rev. 2013;71(7):483–99.

    CrossRef  PubMed  Google Scholar 

  76. Chassaing B, Koren O, Goodrich JK, Poole AC, Srinivasan S, Ley RE, et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature. 2015;519(7541):92–6.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  77. Martinez-Medina M, Denizot J, Dreux N, Robin F, Billard E, Bonnet R, et al. Western diet induces dysbiosis with increased e coli in CEABAC10 mice, alters host barrier function favouring AIEC colonisation. Gut. 2014;63(1):116–24.

    CrossRef  PubMed  CAS  Google Scholar 

  78. Schroeder BO, Birchenough GMH, Ståhlman M, Arike L, Johansson MEV, Hansson GC, et al. Bifidobacteria or fiber protects against diet-induced microbiota-mediated colonic mucus deterioration. Cell Host Microbe. 2017:27–40.

    Google Scholar 

  79. Leclercq S, Matamoros S, Cani PD, Neyrinck AM, Jamar F, Stärkel P, et al. Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proc Natl Acad Sci U S A. 2014;111(42):E4485–93.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  80. Setshedi M, Wands JR, De Monte SM. Acetaldehyde adducts in alcoholic liver disease. Oxidative Med Cell Longev. 2016;3(March):178–85.

    Google Scholar 

  81. Forbes JD, Van Domselaar G, Bernstein CN. The gut microbiota in immune-mediated inflammatory diseases. Front Microbiol. 2016;7:1081.

    Google Scholar 

  82. Bunker JJ, Flynn TM, Koval JC, Shaw DG, Meisel M, McDonald BD, et al. Innate and adaptive humoral responses coat distinct commensal bacteria with immunoglobulin A. Immunity. 2015;43(3):541–53.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  83. Seki E, De Minicis S, Österreicher CH, Kluwe J, Osawa Y, Brenner DA, et al. TLR4 enhances TGF-β signaling and hepatic fibrosis. Nat Med. 2007;13(11):1324–32.

    CrossRef  CAS  PubMed  Google Scholar 

  84. Gäbele E, Mühlbauer M, Dorn C, Weiss TS, Froh M, Schnabl B, et al. Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem Biophys Res Commun. 2008;376(2):271–6.

    CrossRef  PubMed  CAS  Google Scholar 

  85. Hartmann P, Haimerl M, Mazagova M, Brenner D, Schnabl B. Toll-Like Receptor 2 mediated intestinal injury and enteric tumor necrosis factor receptor I contribute to liver fibrosis in mice. Gastroenterology. 2012;143(5):1330–40.

    CrossRef  CAS  PubMed  Google Scholar 

  86. Yang AM, Inamine T, Hochrath K, Chen P, Wang L, Llorente C, et al. Intestinal fungi contribute to development of alcoholic liver disease. J Clin Invest. 2017;127(7):2829–41.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  87. Tilg H, Moschen AR, Szabo G. Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2016;64(3):955–65.

    CrossRef  CAS  PubMed  Google Scholar 

  88. Seki E, Schnabl B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol. 2012;590(3):447–58.

    CrossRef  CAS  PubMed  Google Scholar 

  89. Zeisel SH, Da Costa KA. Choline: an essential nutrient for public health. Nutr Rev. 2009;67(11):615–23.

    CrossRef  PubMed  Google Scholar 

  90. Mehedint MG, Zeisel SH. Choline’s role in maintaining liver function: new evidence for epigenetic mechanisms. Curr Opin Clin Nutr Metab Care. 2013;16(3):339–45.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  91. Chen YM, Liu Y, Zhou RF, Chen XL, Wang C, Tan XY, et al. Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. Sci Rep. 2016;6:19076.

    Google Scholar 

  92. Velasquez MT, Ramezani A, Manal A, Raj DS. Trimethylamine N-oxide: the good, the bad and the unknown. Toxins (Basel). 2016;8(11):326.

    CrossRef  PubMed Central  CAS  Google Scholar 

  93. Mima K, Nakagawa S, Sawayama H, Ishimoto T, Imai K, Iwatsuki M, et al. The microbiome and hepatobiliary-pancreatic cancers. Cancer Lett. 2017;402:9–15.

    CrossRef  CAS  PubMed  Google Scholar 

  94. Dapito DH, Mencin A, Gwak G-Y, Pradere J-P, Jang M-K, Mederacke I, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell. 2012;21(4):504–16.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  95. Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013;499(7456):97–101.

    CrossRef  CAS  PubMed  Google Scholar 

  96. Xie G, Wang X, Huang F, Zhao A, Chen W, Yan J, et al. Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis. Int J Cancer. 2016;139(8):1764–75.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  97. Gomes AL, Teijeiro A, Burén S, Tummala KS, Yilmaz M, Waisman A, et al. Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma. Cancer Cell. 2016;30(1):161–75.

    CrossRef  CAS  PubMed  Google Scholar 

  98. Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillère R, Hannani D, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342(6161):971–6.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  99. Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab. 2017;25(5):1054–62.e5.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  100. Madrid AM, Hurtado C, Venegas M, Cumsille F, Defilippi C. Long-term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function. Am J Gastroenterol. 2001;96(4):1251–5.

    CrossRef  CAS  PubMed  Google Scholar 

  101. Wiest R, Albillos A, Trauner M, Bajaj JS, Jalan R. Targeting the gut-liver axis in liver disease. J Hepatol. 2017;67(5):1084–103.

    CrossRef  CAS  PubMed  Google Scholar 

  102. Kirpich IA, Solovieva NV, Leikhter SN, Shidakova NA, Lebedeva OV, Sidorov PI, et al. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol. 2008;42(8):675–82.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  103. Li J, Sung CYJ, Lee N, Ni Y, Pihlajamäki J, Panagiotou G, et al. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc Natl Acad Sci U S A. 2016;113(9):E1306–15.

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  104. Thiele M, Wiest R, Gluud LL, Albillos A, Krag A. Can non-selective beta-blockers prevent hepatocellular carcinoma in patients with cirrhosis? Med Hypotheses. 2013;81(5):871–4.

    CrossRef  CAS  PubMed  Google Scholar 

  105. Reiberger T, Ferlitsch A, Payer BA, Mandorfer M, Heinisch BB, Hayden H, et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol. 2013;58(5):911–21.

    CrossRef  CAS  PubMed  Google Scholar 

  106. de Groot PF, Frissen MN, de Clercq NC, Nieuwdorp M. Fecal microbiota transplantation in metabolic syndrome: history, present and future. Gut Microbes. 2017;8(3):253–67.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  107. Drekonja D, Reich J, Gezahegn S, Greer N, Shaukat A, MacDonald R, et al. Fecal microbiota transplantation for clostridium difficile infection a systematic review. Ann Intern Med. 2015;162(9):630–8.

    CrossRef  PubMed  Google Scholar 

  108. Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JFWM, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143(4):913–916.e7.

    CrossRef  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

    Anne Lundager Madsen, Thorsten Brach, Timo Kern, Emilie Glad Bak, Trine Nielsen & Manimozhiyan Arumugam

Authors
  1. Anne Lundager Madsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thorsten Brach
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Timo Kern
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emilie Glad Bak
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Trine Nielsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Manimozhiyan Arumugam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manimozhiyan Arumugam .

Editor information

Editors and Affiliations

  1. Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark

    Prof. Aleksander Krag

  2. The Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, University of Copenhagen, Copenhagen, Denmark

    Torben Hansen

Rights and permissions

Reprints and Permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Madsen, A.L., Brach, T., Kern, T., Bak, E.G., Nielsen, T., Arumugam, M. (2019). The Role of the Bacterial Microbiota in Alcoholic and Non-alcoholic Fatty Liver Disease. In: Krag, A., Hansen, T. (eds) The Human Gut-Liver-Axis in Health and Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-98890-0_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-98890-0_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-98889-4

  • Online ISBN: 978-3-319-98890-0

  • eBook Packages: MedicineMedicine (R0)

search

Navigation